New Guidance Issued for Multivessel PCI, Thrombectomy in Heart Attack Patients

Updates address new evidence from PRAMI, CvLPRIT and other trials

Contact: Rachel Cagan,, 202-375-6395

WASHINGTON (Oct 21, 2015) -

New guidance on the use of multivessel coronary interventions and thrombectomy in patients with heart attacks due to completely blocked arteries was issued today in a focused update from the American College of Cardiology, the American Heart Association, and the Society for Cardiovascular Angiography and Interventions, in collaboration with the American College of Emergency Physicians.

The focused update on primary percutaneous coronary intervention (PCI) for patients with ST-elevation myocardial infarction (STEMI) was published online today. Its scope was limited to the setting of primary PCI and the relevant considerations for multivessel PCI and thrombus aspiration.

“While we knew that treating the culprit artery that is completely blocked by implanting a stent is beneficial, it was previously not considered safe to treat other partially blocked (nonculprit) arteries during the same procedure,” said Glenn N. Levine, MD, FACC, FAHA, co-chair of the writing committee, professor of medicine at Baylor College of Medicine, and director of the cardiac care unit at the Michael E. DeBakey VA Medical Center in Houston. He is also chair-elect of the ACC/AHA Task Force on Clinical Practice Guidelines.

New evidence from recent clinical trials has shown that treating other partially blocked arteries may be safe and beneficial in selected patients with multivessel disease. The focused update states that treating the other blocked arteries with a stent may be considered in patients with STEMI who are hemodynamically stable at the time of the primary PCI (Class IIb recommendation).

In past iterations of the guidelines, treatment of other partially blocked arteries at the time of primary PCI was given a Class III-harm recommendation. This recommendation was based on prior nonrandomized study data, which suggested worse outcomes in patients who underwent contemporaneous PCI of vessels other than the one causing the heart attack.

The new recommendation states that “PCI of a noninfarct artery may be considered in selected patients with STEMI and multivessel disease who are hemodynamically stable, either at the time of primary PCI or as a planned staged procedure,” and designates this as a Class IIb recommendation. This recommendation was based on the results from four recent randomized clinical trials (PRAMI, CvLPRIT, DANAMI 3-PRIMULTI, PRAGUE-13) that did not demonstrate an increased risk of harm when performing multivessel PCI. As well, in three of the four studies, multivessel PCI was beneficial.

The best timing to treat non-culprit arteries, however, is not known, and no recommendation on timing of treating these other arteries was made because of insufficient evidence. The focused update states that “physicians should integrate clinical data, lesion severity/complexity, and the risk of contrast nephropathy to determine the optimal strategy” when considering the indications for and timing of multivessel PCI (primary or staged).

Despite this change in the recommendation regarding multivessel PCI in hemodynamically stable patients, the writing committee emphasized that it is not an endorsement of its routine use in all patients with STEMI and multivessel disease.

The recommendation for the routine use of manual aspiration thrombectomy prior to a primary PCI procedure to implant a stent, using a device to aspirate or create suction to remove the blood clot from the blocked artery, was downgraded to Class III (no benefit) from Class IIa (is reasonable) for patients with a heart attack due to completely blocked arteries. The change in this recommendation was based on the results of three recent randomized trials (INFUSE-AMI, TASTE, and TOTAL), as well as an analysis of all available data on this procedure.

“Based on new evidence, the writing group concluded that there was no benefit with the routine use of aspiration thrombectomy,” stated Dr. Levine. Whether a selective or “bailout” use of aspiration thrombectomy in some patients has any usefulness is not well established, and to date no specific patient subgroup that may benefit from aspiration thrombectomy has been identified.

“This document is intended to provide a timely update based on new evidence to assist clinical decision-making,” stated Dr. Levine. The main document and its online data supplement provide further details to inform decision-making in individual cases.

The paper will be published online today in the Journal of the American College of Cardiology, Circulation and Catheterization and Cardiovascular Interventions.

About the American College of Cardiology

The American College of Cardiology is a 49,000-member medical society that is the professional home for the entire cardiovascular care team. The mission of the College is to transform cardiovascular care and to improve heart health. The ACC leads in the formation of health policy, standards and guidelines. The College operates national registries to measure and improve care, provides professional medical education, disseminates cardiovascular research and bestows credentials upon cardiovascular specialists who meet stringent qualifications. For more information, visit

About the American Heart Association

The American Heart Association is devoted to saving people from heart disease and stroke - America's No. 1 and No. 4 killers. We team with millions of volunteers to fund innovative research, fight for stronger public health policies, and provide lifesaving tools and information to prevent and treat these diseases. The Dallas-based association is the nation’s oldest and largest voluntary organization dedicated to fighting heart disease and stroke. To learn more or to get involved, call 1-800-AHA-USA1, visit or call any of our offices around the country. Follow us on Facebook and Twitter.

About the Society for Cardiovascular Angiography and Interventions

The Society for Cardiovascular Angiography and Interventions is a 4,500-member professional organization representing invasive and interventional cardiologists and cath lab professionals in approximately 70 nations. SCAI's mission is to promote excellence in invasive/interventional cardiovascular medicine through physician education and representation, and advancement of quality standards to enhance patient care. SCAI's public education program, Seconds Count, offers comprehensive information about cardiovascular disease. For more information about SCAI and Seconds Count, visit or


< Back to Listings